Antibodies

1. Front Matter

   Pages i-xvi

   PDF

2. Transgenic Technology for Monoclonal Antibody Production

   • Steve Sensoli

   Pages 1-11

3. Generation, Engineering and Production of Human Antibodies Using Hucal®

   • Ralf Ostendorp, Christian Frisch, Margit Urban

   Pages 13-52

4. Achieving Appropriate Glycosylation During the Scaleup of Antibody Production

   • X. K. Deng, T. Shantha Raju, K. John Morrow Jr

   Pages 53-78

5. Approaches to Devise Antibody Purification Processes by Chromatography

   • Egisto Boschetti

   Pages 79-103

6. Novel Hiv Neutralizing Antibodies Selected from Phage Display Libraries

   • Maxime Moulard, Mei-Yun Zhang, Dimiter S. Dimitrov

   Pages 105-117

7. Monoclonal and Bispecific Antibodies in Combination with Radiotherapy for Cancer Treatment

   • David Azria, Christel Larbouret, Bruno Robert, Mahmut Ozsahin, Jean-Bernard Dubois, André Pèlegrin

   Pages 119-139

8. Antibodies, a Potent Tool to Target Genes into Designated Cells and Tissues

   • Francois Hirsch, Olivier Deas, Gabrielle Carvalho, Antoine Dürrbach, Dominique Thierry, Alain Chapel

   Pages 141-155

9. Intrabodies: Development and Application in Functional Genomics and Therapy

   • Alcide Barberis, Adrian Auf Der Maur, Kathrin Tissot, Peter Lichtlen

   Pages 157-168

10. Expression of Recombinant Antibodies by Tumour Cells: On Road to Anti-Tumour Therapy

    • Emmanuelle Bonnin, Jean-Luc Teillaud

    Pages 169-182

11. Antitumor Antibodies: From Research to Clinic

    • Sylvie Ménard, Serenella M. Pupa, Manuela Campiglio, Elda Tagliabue

    Pages 183-187

12. Macrophages for Immunotherapy

    • Delphine Loirat, Sylvie Jacod, Aurélie Boyer, Fabrice Auzelle, Andrès McAllister, Jean-Pierre Abastado et al.

    Pages 189-197

13. Future Prospects in Antibody Engineering and Therapy

    • Sophie Siberil, Jean-Luc Teillaud

    Pages 199-215

14. Back Matter

    Pages 217-232

    PDF

It is now over one hundred years since von Behring and Kitsato first concluded experiments that led to the use of passive immunisation, employing antibodies raised in animals against tetanus and diphtheria toxins. The advancement of technology both in manufacturing purity product in a cost effective way and the clinical research has proved that antibodies are one ofthe most successful products in biotechnology. Monoclonal antibodies account for between one-third and one-halfof all pharmaceutical products in development and human clinical trials. Both the nature of monoclonal antibody therapies and the relatively large size of the monoclonal antibody dictate the production requirements, for many ofthese therapeutics the monoclonal antibody product will be 100 kilogrammes or more per year. It is widely acknowledged that there is currently a worldwide shortage of biomanufacturing capacity, and the active pharmaceutical ingredient material requirements for these products are expected to increase. Thus the industry is looking for new sources and extensive studies are being carried out not only for alternative technology to meet the needs but also to reveal the new therapeutic applicationsofantibodies. This book brings to the forefront current advances in novel technologies for the manufacturing of monoclonal antibodies and also their extensive clinical importance. The first four chapters give an overview of the new technologies and the successful application in the manufacture of monoclonal antibodies with clinical purity. The next chapters address the application of antibodies in cancer therapy and functional genomic therapy.

• HIV
• cancer
• cancer therapy
• cells
• development
• future
• immunotherapy
• kinetics
• macrophages
• manufacturing
• pharmaceutical
• pharmacokinetics
• research
• safety
• tissue

• Littlebourne, Kent, UK

  G. Subramanian

Policies and ethics